Which hedge funds own URGN? UROGEN PHARMA LTD, Q2 2026 13F holders
40 tracked hedge funds disclosed a position in URGN (UROGEN PHARMA LTD) in their Q2 2026 13F filings, worth $652.3m in total. The largest holder by portfolio weight is Silverarc Capital Management, LLC at 5.3% of its book. 11 opened a new position this quarter: Verdad Advisers, LP, Birchview Capital, LP, Point72 Asset Management, L.P., Polen Capital. 6 exited: Paradigm Biocapital Advisors LP, Vestal Point Capital, LP, ExodusPoint Capital Management, LP.
- 40
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 11
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 6
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $63.0m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $36.0m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $652m
- Combined value Sum of the holders' reported positions in the security.
- 3.2%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Paradigm Biocapital Advisors LP | 0.6% | $30.6m |
| Vestal Point Capital, LP | 0.07% | $2.5m |
| ExodusPoint Capital Management, LP | 0.01% | $1.3m |
| Trexquant Investment LP | 0.01% | $1.3m |
| Caption Management, LLC | 0.0% | $74.2k |
| Farallon Capital Management, L.L.C. | 0.0% | $198k |
Ownership over time
Who discovered URGN first? Beta
The run: Q4 2024 → Q3 2026, +282%
| Superstring Capital Management LP high conviction | Q4 2024 | 2.8% | +5.5 pts |
| Opaleye Management Inc. | Q2 2024 | 0.4% | +3.9 pts |
| Stonepine Capital Management, LLC | Q3 2024 | 2.8% | +0.5 pts |
| Nantahala Capital Management, LLC | Q4 2024 | 1.0% | +0.3 pts |
| DAFNA Capital Management LLC | Q2 2024 | 1.3% | +0.2 pts |
| Vestal Point Capital, LP | Q4 2024 | 1.0% | 0.0 pts |
| Cormorant Asset Management, LP | Q2 2024 | 0.2% | −0.6 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.